

CITATION REPORT

List of articles citing

Glycogen synthase kinase-3 induces Alzheimer's disease-like phosphorylation of tau: generation of paired helical filament epitopes and neuronal localisation of the kinase

DOI: 10.1016/0304-3940(92)90774-2
Neuroscience Letters, 1992, 147, 58-62.

Source: <https://exaly.com/paper-pdf/23335091/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
656	Immunological and biochemical study on tissue and subcellular distributions of protein kinase FA (an activating factor of ATP.Mg-dependent protein phosphatase): a simplified and efficient procedure for high quantity purification from brain. 1993 , 12, 667-76		22
655	Developmental changes in tau phosphorylation: fetal tau is transiently phosphorylated in a manner similar to paired helical filament-tau characteristic of Alzheimer's disease. 1993 , 61, 2071-80		148
654	Protein kinase FA/GSK-3 phosphorylates tau on Ser235-Pro and Ser404-Pro that are abnormally phosphorylated in Alzheimer's disease brain. 1993 , 61, 1742-7		77
653	A cdc2-related kinase PSSALRE/cdk5 is homologous with the 30 kDa subunit of tau protein kinase II, a proline-directed protein kinase associated with microtubule. 1993 , 335, 171-5		196
652	Dephosphorylation of tau protein and Alzheimer paired helical filaments by calcineurin and phosphatase-2A. 1993 , 336, 425-32		126
651	Glycogen synthase kinase 3 beta is identical to tau protein kinase I generating several epitopes of paired helical filaments. 1993 , 325, 167-72		320
650	Tau protein and the neurofibrillary pathology of Alzheimer's disease. 1993 , 16, 460-5		516
649	Abnormal Alzheimer-like phosphorylation of tau-protein by cyclin-dependent kinases cdk2 and cdk5. 1993 , 336, 417-24		367
648	Phosphorylation of Ser262 strongly reduces binding of tau to microtubules: distinction between PHF-like immunoreactivity and microtubule binding. 1993 , 11, 153-63		642
647	Abnormal tau phosphorylation at Ser396 in Alzheimer's disease recapitulates development and contributes to reduced microtubule binding. 1993 , 10, 1089-99		765
646	Tau as a marker for Alzheimer's disease. 1993 , 18, 480-3		102
645	Tau protein kinase I is essential for amyloid beta-protein-induced neurotoxicity. 1993 , 90, 7789-93		349
644	Expression and processing of pathologic proteins in alzheimer's disease. 1993 , 3, 227-237		13
643	Cellular and molecular pathology in alzheimer's disease. 1993 , 3, 270-287		41
642	Epitope mapping of monoclonal antibodies to the paired helical filaments of Alzheimer's disease: identification of phosphorylation sites in tau protein. <i>Biochemical Journal</i> , 1994 , 301 (Pt 3), 871-7	3.8	328
641	Tyrosine dephosphorylation and concurrent inactivation of protein kinase FA/GSK-3 alpha by genistein in A431 cells. 1994 , 56, 131-41		28
640	Tumor promoter phorbol ester reversibly modulates tyrosine dephosphorylation/inactivation of protein kinase FA/GSK-3 alpha in A431 cells. 1994 , 56, 550-8		13

639	Alzheimer's disease: Recent advances in molecular pathology and genetics. 1994 , 9, 431-444		7
638	Alzheimer's disease-like phosphorylation of the microtubule-associated protein tau by glycogen synthase kinase-3 in transfected mammalian cells. 1994 , 4, 1077-86		414
637	Dorothy Russell Memorial Lecture. The molecular pathology of Alzheimer's disease: are we any closer to understanding the neurodegenerative process?. 1994 , 20, 322-38		21
636	PHF-tau from Alzheimer's brain comprises four species on SDS-PAGE which can be mimicked by in vitro phosphorylation of human brain tau by glycogen synthase kinase-3 beta. 1994 , 349, 359-64		83
635	Assembly of Alzheimer-like filaments from full-length tau protein. 1994 , 337, 135-8		126
634	Dephosphorylation of tau protein from Alzheimer's disease patients. <i>Neuroscience Letters</i> , 1994 , 165, 175-8	3-3	13
633	Aluminum modifies the properties of Alzheimer's disease PHF tau proteins in vivo and in vitro. 1994 , 14, 7221-33		111
632	Detection of phosphorylated Ser262 in fetal tau, adult tau, and paired helical filament tau. 1995 , 270, 18917-22		277
631	Dephosphorylation of fetal-tau and paired helical filaments-tau by protein phosphatases 1 and 2A and calcineurin. 1995 , 118, 1224-31		39
630	The phosphorylation state of the microtubule-associated protein tau as affected by glutamate, colchicine and beta-amyloid in primary rat cortical neuronal cultures. <i>Biochemical Journal</i> , 1995 , 309 (Pt 3), 941-9	3-8	79
629	Tau protein in Alzheimer's disease. 1995 , 23, 80-5		28
628	Activation of a neurofilament kinase, a tau kinase, and a tau phosphatase by decreased ATP levels in nerve growth factor-differentiated PC-12 cells. 1995 , 92, 1861-5		28
627	Hyperphosphorylation of Tau and filopodial retraction following microinjection of protein kinase C catalytic subunits. 1995 , 42, 648-56		40
626	Overexpression of cellular activity and protein level of protein kinase FA/GSK-3 alpha correlates with human thyroid tumor cell dedifferentiation. 1995 , 58, 474-80		20
625	Dysfunction of protein kinase FA/GSK-3 alpha in lymphocytes of patients with schizophrenic disorder. 1995 , 59, 108-16		22
624	Association of protein kinase FA/GSK-3alpha (a proline-directed kinase and a regulator of protooncogenes) with human cervical carcinoma dedifferentiation/progression. 1995 , 59, 143-50		19
623	Tau protein kinase I/GSK-3 beta/kinase FA in heparin phosphorylates tau on Ser199, Thr231, Ser235, Ser262, Ser369, and Ser400 sites phosphorylated in Alzheimer disease brain. 1995 , 14, 95-105		51
622	Regulation of nuclear transcription factors by stress signals. 1995 , 22, 281-3		28

621	Somatodendritic localization and hyperphosphorylation of tau protein in transgenic mice expressing the longest human brain tau isoform.. <i>EMBO Journal</i> , 1995 , 14, 1304-1313	13	313
620	Molecular determinants of paired helical filament assembly and its therapeutic implications in Alzheimer's disease. 1995 , 7, 299-338		1
619	Microtubule-associated protein/microtubule affinity-regulating kinase (p110mark). A novel protein kinase that regulates tau-microtubule interactions and dynamic instability by phosphorylation at the Alzheimer-specific site serine 262. 1995 , 270, 7679-88		280
618	Cell cycle-dependent phosphorylation and microtubule binding of tau protein stably transfected into Chinese hamster ovary cells. 1995 , 6, 1397-410		95
617	The Amyloid Peptide and Its Precursor in Alzheimer's Disease. 1995 , 6,		23
616	Domains of tau protein, differential phosphorylation, and dynamic instability of microtubules. 1995 , 6, 1887-902		264
615	Control of microtubule polymerization and stability. 1995 , 1, 47-85		1
614	Overexpressed tau protein in cultured cells is phosphorylated without formation of PHF: implication of phosphoprotein phosphatase involvement. 1995 , 34, 1-17		56
613	Dephosphorylation of abnormal sites of tau factor by protein phosphatases and its implication for Alzheimer's disease. 1995 , 26, 205-15		30
612	Glycogen synthase kinase-3 beta phosphorylates tau protein at multiple sites in intact cells. <i>Neuroscience Letters</i> , 1995 , 197, 149-53	3-3	189
611	Analysis of phosphorylation of tau with antibodies specific for phosphorylation sites. <i>Neuroscience Letters</i> , 1995 , 202, 81-4	3-3	82
610	Calcineurin (phosphatase 2B) is present in neurons containing neurofibrillary tangles and in a subset of senile plaques in Alzheimer's disease. 1995 , 4, 13-21		13
609	Shift from fetal-type to Alzheimer-type phosphorylated Tau proteins in SKNSH-SY 5Y cells treated with okadaic acid. 1995 , 357, 197-201		27
608	Stimulation of MAP kinase by v-raf transformation of fibroblasts fails to induce hyperphosphorylation of transfected tau. 1995 , 365, 42-6		38
607	Glycogen synthase kinase 3 phosphorylates recombinant human tau protein at serine-262 in the presence of heparin (or tubulin). 1995 , 372, 65-8		33
606	Tau isoform expression and phosphorylation state during differentiation of cultured neuronal cells. 1995 , 375, 243-8		64
605	Microtubules, Tau Protein, and Paired Helical Filaments in Alzheimer's Disease. 1995 , 143-160		
604	Modulation of PHF-like tau phosphorylation in cultured neurones and transfected cells. 1995 , 16, 389-97; discussion 398-402		37

603	Networking with proline-directed protein kinases implicated in tau phosphorylation. 1995 , 16, 247-56; discussion 257-61		55
602	Molecular dissection of the paired helical filament. 1995 , 16, 325-34		81
601	Alzheimer neurofibrillary lesions: molecular nature and potential roles of different components. 1995 , 16, 381-7		46
600	Isolation of a phosphorylated soluble tau fraction from Alzheimer's disease brain. 1995 , 16, 515-22		21
599	Glycogen synthase kinase 3 alpha and 3 beta do not colocalize with neurofibrillary tangles. 1996 , 17, 343-8		16
598	Structure, microtubule interactions, and phosphorylation of tau protein. 1996 , 777, 96-106		98
597	Regulation of tau phosphorylation in Alzheimer's disease. 1996 , 777, 107-13		37
596	Neurofibrillary tangles of Alzheimer's disease brains contain 14-3-3 proteins. <i>Neuroscience Letters</i> , 1996 , 209, 57-60	3.3	151
595	Site-specific regulation of Alzheimer-like tau phosphorylation in living neurons. 1996 , 72, 167-84		32
594	Phosphorylation of tau by glycogen synthase kinase-3 beta in intact mammalian cells: the effects on the organization and stability of microtubules. 1996 , 73, 1145-57		182
593	AD2, a phosphorylation-dependent monoclonal antibody directed against tau proteins found in Alzheimer's disease. 1996 , 39, 79-88		136
592	Phosphatase inhibition in human neuroblastoma cells alters tau antigenicity and renders it incompetent to associate with exogenous microtubules. 1996 , 380, 63-7		17
591	Characterization of mAb AP422, a novel phosphorylation-dependent monoclonal antibody against tau protein. 1996 , 384, 25-30		121
590	A spatial gradient of tau protein phosphorylation in nascent axons. 1996 , 16, 5727-40		233
589	Schizosaccharomyces pombe skp1+ encodes a protein kinase related to mammalian glycogen synthase kinase 3 and complements a cdc14 cytokinesis mutant. 1996 , 16, 179-91		44
588	A molecular mechanism for the effect of lithium on development. 1996 , 93, 8455-9		1987
587	Tau protein is phosphorylated by cyclic AMP-dependent protein kinase and calcium/calmodulin-dependent protein kinase II within its microtubule-binding domains at Ser-262 and Ser-356. <i>Biochemical Journal</i> , 1996 , 316 (Pt 2), 655-60	3.8	123
586	Immunocytochemistry of tau phosphoserine 413 and tau protein kinase I in Alzheimer pathology. 1996 , 737, 119-32		69

585	Preferential labeling of Alzheimer neurofibrillary tangles with antisera for tau protein kinase (TPK) I/glycogen synthase kinase-3 beta and cyclin-dependent kinase 5, a component of TPK II. 1996 , 92, 232-41	205
584	Glycogen synthase kinase 3 alteration in Alzheimer disease is related to neurofibrillary tangle formation. 1996 , 29, 253-61	63
583	Phosphorylation and dephosphorylation in the proline-rich C-terminal domain of microtubule-associated protein 2. 1996 , 241, 765-71	44
582	Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells. 1996 , 6, 1664-8	1150
581	It takes Tau to tangle. 1996 , 11, 363-368	
580	Induction of lysosomal abnormalities and tau hyperphosphorylation in human neuroblastoma cells by colchicine and okadaic acid: Evidence that microtubule disruption contributes to alzheimer neurodegeneration. 1996 , 19, 27-36	4
579	Calphostin C induces tyrosine dephosphorylation/inactivation of protein kinase Fa/GSK-3β in a pathway independent of tumor promoter phorbol ester-mediated down-regulation of protein kinase C. 1996 , 60, 121-129	4
578	Okadaic acid, sphingosine, and phorbol ester reversibly modulate heat induction on protein kinase Fa/GSK-3β in A431 cells. 1996 , 60, 218-225	6
577	Non-proline-dependent protein kinases phosphorylate several sites found in tau from Alzheimer disease brain. 1996 , 154, 143-51	41
576	Glycogen synthase kinase 3 phosphorylation of different residues in the presence of different factors: analysis on tau protein. 1996 , 165, 47-54	25
575	Site-specific dephosphorylation of tau protein at Ser202/Thr205 in response to microtubule depolymerization in cultured human neurons involves protein phosphatase 2A. 1996 , 271, 5589-94	65
574	Insulin and insulin-like growth factor-1 regulate tau phosphorylation in cultured human neurons. 1997 , 272, 19547-53	381
573	Alzheimer-like changes in microtubule-associated protein Tau induced by sulfated glycosaminoglycans. Inhibition of microtubule binding, stimulation of phosphorylation, and filament assembly depend on the degree of sulfation. 1997 , 272, 33118-24	148
572	τ Protein and the Neurofibrillary Pathology of Alzheimer's Disease. 1997 , 199-218	2
571	The Neurofibrillary Pathology of Alzheimer's Disease. 1997 , 3, 131-141	10
570	Effect of increased glycogen synthase kinase-3 activity upon the maturation of the amyloid precursor protein in transfected cells. 1997 , 8, 639-43	37
569	Tau phosphorylation in transgenic mice expressing glycogen synthase kinase-3beta transgenes. 1997 , 8, 3251-5	95
568	Phosphorylation of tau by glycogen synthase kinase 3beta affects the ability of tau to promote microtubule self-assembly. <i>Biochemical Journal</i> , 1997 , 323 (Pt 3), 741-7	3.8 79

567	Muscarinic therapies in Alzheimer's disease; from palliative treatments to disease modification. 1997 , 1, 15-20		1
566	Selective phosphorylation of adult tau isoforms in mature hippocampal neurons exposed to fibrillar A beta. 1997 , 9, 220-34		160
565	Mechanisms of neurotoxicity associated with amyloid beta deposition and the role of free radicals in the pathogenesis of Alzheimer's disease: a critical appraisal. 1997 , 10, 518-26		106
564	Changes in the ageing brain in health and disease. 1997 , 352, 1781-92		54
563	Normal and pathological Tau proteins as factors for microtubule assembly. 1997 , 171, 167-224		90
562	Selective interaction of protein kinase FA/glycogen synthase kinase-3alpha with membrane phospholipids. 1997 , 237, 331-5		2
561	Activation of the Wnt signaling pathway: a molecular mechanism for lithium action. 1997 , 185, 82-91		532
560	Phosphorylation events mediated by protein kinase C alpha and epsilon participate in regulation of tau steady-state levels and generation of certain "Alzheimer-like" phospho-epitopes. 1997 , 15, 295-307		14
559	Phosphorylation of microtubule-associated protein tau by stress-activated protein kinases. 1997 , 409, 57-62		230
558	Overexpression of the mouse dishevelled-1 protein inhibits GSK-3beta-mediated phosphorylation of tau in transfected mammalian cells. 1997 , 411, 369-72		45
557	Tau protein in the glial cytoplasmic inclusions of multiple system atrophy can be distinguished from abnormal tau in Alzheimer's disease. <i>Neuroscience Letters</i> , 1997 , 230, 49-52	3-3	94
556	The phosphorylation of tau: a critical stage in neurodevelopment and neurodegenerative processes. 1997 , 78, 309-24		271
555	Elevated protein levels of protein phosphatases PP-2A and PP-2B in astrocytes of Alzheimer's disease temporal cortex. 1997 , 104, 1329-38		12
554	Beta-amyloid and ionophore A23187 evoke tau hyperphosphorylation by distinct intracellular pathways: differential involvement of the calpain/protein kinase C system. 1997 , 49, 759-68		33
553	Accumulation of cyclin-dependent kinase 5 (cdk5) in neurons with early stages of Alzheimer's disease neurofibrillary degeneration. 1998 , 797, 267-77		195
552	The interrelationship between selective tau phosphorylation and microtubule association. 1998 , 798, 173-83		55
551	Elution of unmodified oligodeoxynucleotides from zinc-imidazole negatively stained polyacrylamide gels. 1998 , 264, 127-9		3
550	An assay for glycogen synthase kinase 3 (GSK-3) for use in crude cell extracts. 1998 , 264, 124-7		68

549	Beta-amyloid induced hyperphosphorylation of tau in human neuroblastoma cells involves map kinase. 1998 , 22, 45-49	8
548	Divergent influences of protein kinase C isoforms on intracellular levels of phosphorylated and non-phosphorylated tau immunoreactivity. 1998 , 22, 51-57	
547	Subcellular distribution of protein phosphatases and abnormally phosphorylated tau in the temporal cortex from Alzheimer's disease and control brains. 1998 , 105, 69-83	53
546	Dendritic changes in Alzheimer's disease and factors that may underlie these changes. 1998 , 55, 595-609	86
545	GBP, an inhibitor of GSK-3, is implicated in Xenopus development and oncogenesis. 1998 , 93, 1031-41	292
544	The regulation of phosphorylation of tau in SY5Y neuroblastoma cells: the role of protein phosphatases. 1998 , 426, 248-54	99
543	Isolation and chromosomal mapping of human glycogen synthase kinase-3 and -3 encoding genes. 1998 , 41, 720-727	54
542	The endogenous and cell cycle-dependent phosphorylation of tau protein in living cells: implications for Alzheimer's disease. 1998 , 9, 1495-512	242
541	Neurofibrillary tangles and Alzheimer's disease. 1998 , 40, 130-40	108
540	Essential role for protein kinase B (PKB) in insulin-induced glycogen synthase kinase 3 inactivation. Characterization of dominant-negative mutant of PKB. 1998 , 273, 13150-6	278
539	Neurofibrillary pathology of Alzheimer's disease and other tauopathies. 1998 , 117, 287-306	53
538	Phosphorylation Activity in the Alzheimer's Disease and Normal Brain is Modulated by Microtubule-Associated Protein, Tau in Vitro. <i>Journal of Alzheimerts Disease</i> , 1999 , 1, 169-182	4-3 4
537	Biphasic Effect of Calcium Influx on Tau Phosphorylation: Involvement of Calcium-Dependent Phosphatase and Kinase Activities. <i>Journal of Alzheimerts Disease</i> , 1999 , 1, 353-360	4-3 9
536	cAMP-dependent protein kinase phosphorylations on tau in Alzheimer's disease. 1999 , 19, 7486-94	169
535	Tau phosphorylation both in vitro and in cells. 2000 , 32, 375-93	1
534	Activation of the L voltage-sensitive calcium channel by mitogen-activated protein (MAP) kinase following exposure of neuronal cells to beta-amyloid. MAP kinase mediates beta-amyloid-induced neurodegeneration. 1999 , 274, 30322-7	134
533	Expression analysis of glycogen synthase kinase-3 in human tissues. 1999 , 54, 85-91	90
532	Hierarchical phosphorylation of recombinant tau by the paired-helical filament-associated protein kinase is dependent on cyclic AMP-dependent protein kinase. 1999 , 72, 214-24	54

531	Insulin transiently increases tau phosphorylation: involvement of glycogen synthase kinase-3beta and Fyn tyrosine kinase. 1999 , 72, 576-84		180
530	The order of exposure of tau to signal transduction kinases alters the generation of "AD-like" phosphoepitopes. 1999 , 19, 223-33		13
529	Free PKC catalytic subunits (PKM) phosphorylate tau via a pathway distinct from that utilized by intact PKC. 1999 , 850, 207-16		22
528	Alzheimer's Disease. 1999 ,		
527	Developmental expression and localization of glycogen synthase kinase-3beta in rat brain. 1999 , 16, 279-93		193
526	Elevated neuronal Cdc2-like kinase activity in the Alzheimer disease brain. 1999 , 34, 21-9		137
525	Phosphorylation of tau protein by recombinant GSK-3beta: pronounced phosphorylation at select Ser/Thr-Pro motifs but no phosphorylation at Ser262 in the repeat domain. 1999 , 454, 157-64		73
524	Lithium reduces tau phosphorylation: effects in living cells and in neurons at therapeutic concentrations. 1999 , 45, 995-1003		131
523	Transgenic expression of the shortest human tau affects its compartmentalization and its phosphorylation as in the pretangle stage of Alzheimer's disease. <i>American Journal of Pathology</i> , 1999 , 154, 255-70	5.8	182
522	Dynamic regulation of expression and phosphorylation of tau by fibroblast growth factor-2 in neural progenitor cells from adult rat hippocampus. 1999 , 19, 5245-54		97
521	A unifying hypothesis of Alzheimer's disease. IV. Causation and sequence of events. 2000 , 11 Spec No, 213-328		66
520	Induction of Alzheimer-specific Tau epitope AT100 in apoptotic human fetal astrocytes. 2000 , 47, 236-52		17
519	Role of glycogen synthase kinase-3beta in neuronal apoptosis induced by trophic withdrawal. 2000 , 20, 2567-74		418
518	Protein Kinase Protocols. 2000 ,		
517	Glycogen synthase kinase-3beta facilitates staurosporine- and heat shock-induced apoptosis. Protection by lithium. 2000 , 275, 7583-90		254
516	Glycogen synthase kinase-3beta phosphorylates protein tau and rescues the axonopathy in the central nervous system of human four-repeat tau transgenic mice. 2000 , 275, 41340-9		253
515	Assays for glycogen synthase kinase-3 (GSK-3). 2001 , 124, 147-59		5
514	Dishevelled-1 regulates microtubule stability: a new function mediated by glycogen synthase kinase-3beta. 2000 , 151, 83-94		111

513	Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. 2000 , 33, 95-130		1420
512	Lithium therapy and signal transduction. 2000 , 21, 61-4		118
511	Molecular cloning and expression analysis of human glycogen synthase kinase-3 alpha promoter. 2000 , 84, 150-7		6
510	New insights into genetic and molecular mechanisms of brain degeneration in tauopathies. 2000 , 20, 225-44		44
509	Tau mutations in frontotemporal dementia FTDP-17 and their relevance for Alzheimer's disease. 2000 , 1502, 110-21		99
508	Axonal remodeling and synaptic differentiation in the cerebellum is regulated by WNT-7a signaling. 2000 , 100, 525-35		586
507	Neurodegenerative tauopathies. 2001 , 24, 1121-59		2089
506	Lithium inhibits glycogen synthase kinase-3 by competition for magnesium. 2001 , 280, 720-5		406
505	Presenilin binding protein is associated with neurofibrillary alterations in Alzheimer's disease and stimulates tau phosphorylation. <i>American Journal of Pathology</i> , 2001 , 159, 1597-602	5.8	28
504	The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling. 2001 , 65, 391-426		1251
503	Phosphorylation of tau by glycogen synthase kinase 3beta in intact mammalian cells influences the stability of microtubules. <i>Neuroscience Letters</i> , 2001 , 312, 141-4	3.3	56
502	Regulation of microtubule-associated proteins. 2001 , 210, 163-226		153
501	Calpain-mediated degradation of p35 to p25 in postmortem human and rat brains. 2001 , 489, 46-50		116
500	Effects of FTDP-17 mutations on the in vitro phosphorylation of tau by glycogen synthase kinase 3beta identified by mass spectrometry demonstrate certain mutations exert long-range conformational changes. 2001 , 493, 40-4		31
499	Molecular targets of lithium action. 2001 , 41, 789-813		422
498	Apolipoprotein E gene and Alzheimer's disease: is tau the link?. 2001 , 67, 111-20		5
497	Tau Phosphorylation. 2001 , 315-332		5
496	GSK3 takes centre stage more than 20 years after its discovery. <i>Biochemical Journal</i> , 2001 , 359, 1-16	3.8	1140

495	GSK3 takes centre stage more than 20 years after its discovery. <i>Biochemical Journal</i> , 2001 , 359, 1-16	3.8	803
494	Lithium inhibits caspase 3 activation and dephosphorylation of PKB and GSK3 induced by K ⁺ deprivation in cerebellar granule cells. 2001 , 78, 199-206		79
493	PD98059 prevents neurite degeneration induced by fibrillar beta-amyloid in mature hippocampal neurons. 2000 , 74, 125-33		115
492	Activation of glycogen synthase kinase 3 beta (GSK-3beta) by platelet activating factor mediates migration and cell death in cerebellar granule neurons. <i>European Journal of Neuroscience</i> , 2001 , 13, 1913-22		76
491	Akt activity in presenilin 1 wild-type and mutation transfected human SH-SY5Y neuroblastoma cells after serum deprivation and high glucose stress. 2001 , 66, 448-56		11
490	Glycogen synthase kinase-3: properties, functions, and regulation. 2001 , 101, 2527-40		323
489	The renaissance of GSK3. 2001 , 2, 769-76		1247
488	Judging a protein by more than its name: GSK-3. <i>Science Signaling</i> , 2001 , 2001, re12	8.8	169
487	The JNK/c-Jun cascade and Alzheimer's disease. 2002 , 17, 79-88		55
486	Glycogen synthase kinase-3beta is complexed with tau protein in brain microtubules. 2002 , 277, 11933-40		80
485	Tau protein phosphorylation as a therapeutic target in Alzheimer's disease. 2002 , 2, 395-415		49
484	Mood stabilizers, glycogen synthase kinase-3beta and cell survival. 2002 , 7 Suppl 1, S35-45		112
483	An inactive pool of GSK-3 at the leading edge of growth cones is implicated in Semaphorin 3A signaling. 2002 , 157, 211-7		211
482	Valproate regulates GSK-3-mediated axonal remodeling and synapsin I clustering in developing neurons. 2002 , 20, 257-70		145
481	Glycogen synthase kinase-3 inhibition by lithium and beryllium suggests the presence of two magnesium binding sites. 2002 , 290, 967-72		89
480	GSK-3 and the neurodevelopmental hypothesis of schizophrenia. 2002 , 12, 13-25		112
479	Phosphorylation of microtubule-associated protein tau by stress-activated protein kinases in intact cells. 2002 , 515, 151-4		52
478	Human wild-type tau interacts with wingless pathway components and produces neurofibrillary pathology in <i>Drosophila</i> . 2002 , 34, 509-19		431

477	Glycogen synthase kinase 3: an emerging therapeutic target. 2002 , 8, 126-32		337
476	Regulation of neuronal cytoskeleton by lysophosphatidic acid: role of GSK-3. 2002 , 1582, 144-53		58
475	Up-regulation of mitogen-activated protein kinases ERK1/2 and MEK1/2 is associated with the progression of neurofibrillary degeneration in Alzheimer's disease. 2002 , 109, 45-55		180
474	The role of tau in Alzheimer's disease. 2002 , 86, 615-27		50
473	Interactions between GSK3beta and caspase signalling pathways during NGF deprivation induced cell death. <i>Journal of Alzheimerts Disease</i> , 2002 , 4, 291-301	4-3	25
472	Glycogen synthase kinase-3 is activated in neuronal cells by Galpha12 and Galpha13 by Rho-independent and Rho-dependent mechanisms. 2002 , 22, 6863-75		71
471	Role of GSK-3 in Alzheimer's disease pathology. 2002 , 56, 491-510		71
470	Glycogen synthase kinase-3 is associated with neuronal and glial hyperphosphorylated tau deposits in Alzheimer's disease, Pick's disease, progressive supranuclear palsy and corticobasal degeneration. 2002 , 104, 583-91		148
469	Phosphorylation sites on tau identified by nanoelectrospray mass spectrometry: differences in vitro between the mitogen-activated protein kinases ERK2, c-Jun N-terminal kinase and P38, and glycogen synthase kinase-3beta. 2000 , 74, 1587-95		262
468	Alternative splicing isoform of tau protein kinase I/glycogen synthase kinase 3beta. 2002 , 81, 1073-83		142
467	Presenilin-binding protein forms aggresomes in monkey kidney COS-7 cells. 2002 , 82, 819-27		17
466	Axin negatively affects tau phosphorylation by glycogen synthase kinase 3beta. 2002 , 83, 904-13		19
465	Protein kinase FA/glycogen synthase kinase-3 alpha after heparin potentiation phosphorylates tau on sites abnormally phosphorylated in Alzheimer's disease brain. 1994 , 63, 1416-25		39
464	Protein kinase FA/glycogen synthase kinase 3 alpha predominantly phosphorylates the in vivo sites of Ser502, Ser506, Ser603, and Ser666 in neurofilament. 1995 , 64, 1848-54		18
463	Alzheimer's disease neurofibrillary tangles contain mitosis-specific phosphoepitopes. 1996 , 67, 2405-16		46
462	Stress-activated protein kinase/c-jun N-terminal kinase phosphorylates tau protein. 1997 , 68, 1736-44		167
461	Two-dimensional characterization of paired helical filament-tau from Alzheimer's disease: demonstration of an additional 74-kDa component and age-related biochemical modifications. 1997 , 69, 834-44		55
460	A conformation- and phosphorylation-dependent antibody recognizing the paired helical filaments of Alzheimer's disease. 1997 , 69, 2087-95		192

459	Discovery of compounds that will prevent tau pathology. 2002 , 19, 261-6		11
458	Intracellular A-beta amyloid, a sign for worse things to come?. 2002 , 26, 299-316		63
457	Fast axonal transport misregulation and Alzheimer's disease. 2002 , 2, 89-99		75
456	Tau and axonopathy in neurodegenerative disorders. 2002 , 2, 131-50		100
455	Plasticity and the spread of Alzheimer's disease-like changes. 2003 , 28, 1715-23		9
454	Role of protein kinase B in Alzheimer's neurofibrillary pathology. 2003 , 105, 381-92		127
453	Effect of the lipid peroxidation product acrolein on tau phosphorylation in neural cells. 2003 , 71, 863-70		100
452	Tau phosphorylation and kinase activation in familial tauopathy linked to deln296 mutation. 2003 , 29, 23-34		38
451	Identification of Tau and MAP2 as novel substrates of Rho-kinase and myosin phosphatase. 2003 , 87, 780-90		82
450	Molecular targets of lithium action. 2003 , 15, 316-40		23
449	Blockade of HMG-CoA reductase activity causes changes in microtubule-stabilizing protein tau via suppression of geranylgeranylpyrophosphate formation: implications for Alzheimer's disease. <i>European Journal of Neuroscience</i> , 2003 , 17, 93-102	3.5	72
448	Synaptic plasticity and cell cycle activation in neurons are alternative effector pathways: the 'Dr. Jekyll and Mr. Hyde concept' of Alzheimer's disease or the yin and yang of neuroplasticity. 2003 , 71, 83-248		158
447	Up-regulation of phosphorylated/activated p70 S6 kinase and its relationship to neurofibrillary pathology in Alzheimer's disease. <i>American Journal of Pathology</i> , 2003 , 163, 591-607	5.8	251
446	GSK-3: tricks of the trade for a multi-tasking kinase. 2003 , 116, 1175-86		1675
445	Akt/PKB kinase phosphorylates separately Thr212 and Ser214 of tau protein in vitro. 2003 , 1639, 159-68		86
444	Age-related changes of Alzheimer's disease-associated proteins in cynomolgus monkey brains. 2003 , 310, 303-11		71
443	Stress-induced hyperphosphorylation of tau in the mouse brain. 2003 , 535, 183-9		74
442	Regulation of glycogen synthase kinase 3 in human platelets: a possible role in platelet function?. 2003 , 553, 173-8		43

441	Beta-secretase (BACE) and GSK-3 mRNA levels in Alzheimer's disease. 2003 , 116, 155-8		51
440	Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418. 2003 , 278, 45937-45		393
439	Human neurodegenerative disease modeling using <i>Drosophila</i> . 2003 , 26, 627-56		132
438	Glycogen synthase kinase 3beta phosphorylates tau at both primed and unprimed sites. Differential impact on microtubule binding. 2003 , 278, 187-93		178
437	Glycogen synthase kinase-3 beta-mediated tau phosphorylation in cultured cell lines. 2003 , 14, 257-60		59
436	Emerging therapeutics for Alzheimer's disease: an avenue of hope. 2003 , 8, 834-45		8
435	Physiological roles of glycogen synthase kinase-3: potential as a therapeutic target for diabetes and other disorders. 2003 , 3, 281-90		65
434	A divergent canonical WNT-signaling pathway regulates microtubule dynamics: dishevelled signals locally to stabilize microtubules. 2004 , 164, 243-53		178
433	Protein trafficking and Alzheimer's disease. 2004 , 1, 1-10		19
432	Phosphorylation of microtubule-associated protein tau by isoforms of c-Jun N-terminal kinase (JNK). 2004 , 90, 352-8		131
431	GSK3 inhibitors: development and therapeutic potential. 2004 , 3, 479-87		609
430	PS1 activates PI3K thus inhibiting GSK-3 activity and tau overphosphorylation: effects of FAD mutations. <i>EMBO Journal</i> , 2004 , 23, 2586-96	13	226
429	The role of insulin and insulin-like growth factor I in the molecular and cellular mechanisms underlying the pathology of Alzheimer's disease. 2004 , 490, 127-33		195
428	Akt/GSK3beta serine/threonine kinases: evidence for a signalling pathway mediated by familial Alzheimer's disease mutations. 2004 , 16, 187-200		78
427	Tau in neurodegenerative diseases: tau phosphorylation and assembly. 2004 , 6, 477-82		39
426	Glycogen synthase kinase 3beta inhibitor Chir025 reduces neuronal death resulting from oxygen-glucose deprivation, glutamate excitotoxicity, and cerebral ischemia. 2004 , 188, 378-86		84
425	Cyclin-dependent kinase 2 regulates the interaction of Axin with beta-catenin. 2004 , 317, 478-83		13
424	Glycogen synthase kinase-3 is increased in white cells early in Alzheimer's disease. <i>Neuroscience Letters</i> , 2005 , 373, 1-4	3-3	92

423	The role of GSK-3 β in the formation of neurofibrillary tangles. 2004 , 4, S51-S56	1
422	Role of tau protein in both physiological and pathological conditions. 2004 , 84, 361-84	641
421	Deregulation of GSK-3 β and JNK in a Mouse Model of Tauopathy: A Kinase Combination That Induces Alzheimer-Type Tau Hyperphosphorylation. 2004 , 62-70	
420	Activated Protein Kinases and Phosphorylated Tau Protein in Alzheimer Disease. 2004 , 225-235	
419	Functional interactions of tau and their relevance for Alzheimer's disease. 2004 , 1, 255-69	38
418	Induction of hyperphosphorylated tau in primary rat cortical neuron cultures mediated by oxidative stress and glycogen synthase kinase-3. <i>Journal of Alzheimers Disease</i> , 2004 , 6, 659-71; discussion 673-81 ^{4,3}	137
417	[Regulation of phosphorylation of tau by insulin and Ca ²⁺ signals]. 2005 , 125, 129-35	
416	Role of nonfeminizing estrogens in brain protection from cerebral ischemia: an animal model of Alzheimer's disease neuropathology. 2005 , 1052, 233-42	37
415	Acute anoxia induces tau dephosphorylation in rat brain slices and its possible underlying mechanisms. 2005 , 94, 1225-34	29
414	Hyperphosphorylation of microtubule-associated protein tau in senescence-accelerated mouse (SAM). 2005 , 126, 1300-4	116
413	Tau and GSK3 β dephosphorylations are required for regulating Pin1 phosphorylation. 2005 , 30, 955-61	16
412	A novel mass spectrometry-based assay for GSK-3 β activity. 2005 , 6, 29	10
411	Guidance of Axons to Targets in Development and in Disease. 2005 , 447-481	2
410	Choroid plexus megalin is involved in neuroprotection by serum insulin-like growth factor I. 2005 , 25, 10884-93	169
409	Gamma-secretase as a therapeutic target for the treatment of Alzheimer's disease. 2005 , 11, 3363-82	49
408	Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. 2005 , 102, 6990-5	565
407	Proteolysis of non-phosphorylated and phosphorylated tau by thrombin. 2005 , 280, 5145-53	56
406	Evidence that phosphorylation of the microtubule-associated protein Tau by SAPK4/p38 δ at Thr50 promotes microtubule assembly. 2005 , 118, 397-408	106

405	Lithium chloride increases the production of amyloid-beta peptide independently from its inhibition of glycogen synthase kinase 3. 2005 , 280, 33220-7	36
404	Current advances on different kinases involved in tau phosphorylation, and implications in Alzheimer's disease and tauopathies. 2005 , 2, 3-18	248
403	Inhibition of GSK-3beta as a target for cardioprotection: the importance of timing, location, duration and degree of inhibition. 2005 , 9, 447-56	46
402	Intraneuronal beta-amyloid expression downregulates the Akt survival pathway and blunts the stress response. 2005 , 25, 10960-9	100
401	The links between axin and carcinogenesis. 2005 , 58, 225-36	177
400	FRAT-2 preferentially increases glycogen synthase kinase 3 beta-mediated phosphorylation of primed sites, which results in enhanced tau phosphorylation. 2005 , 280, 270-6	12
399	Multinuclear giant cell formation is enhanced by down-regulation of Wnt signaling in gastric cancer cell line, AGS. 2005 , 308, 18-28	13
398	Both the establishment and the maintenance of neuronal polarity require active mechanisms: critical roles of GSK-3beta and its upstream regulators. 2005 , 120, 123-35	448
397	Glycogen synthase kinase 3beta links neuroprotection by 17beta-estradiol to key Alzheimer processes. 2005 , 132, 581-9	103
396	Glycogen synthase kinase 3beta phosphorylates Alzheimer's disease-specific Ser396 of microtubule-associated protein tau by a sequential mechanism. 2006 , 45, 3125-33	100
395	Alzheimer: 100 Years and Beyond. 2006 ,	5
394	Phosphorylation of neuronal cytoskeletal proteins in Alzheimer's disease and Lewy body dementias. 1994 , 747, 92-109	41
393	Tau phosphorylation and aggregation in Alzheimer's disease pathology. 2006 , 580, 2922-7	182
392	PTEN, a negative regulator of PI3 kinase signalling, alters tau phosphorylation in cells by mechanisms independent of GSK-3. 2006 , 580, 3121-8	48
391	Cyclin-dependent protein kinase 5 primes microtubule-associated protein tau site-specifically for glycogen synthase kinase 3beta. 2006 , 45, 3134-45	113
390	Involvement of apoptosis and cholinergic dysfunction in Alzheimer's disease. 2006 , 6, S57-S63	1
389	Molecular biology, pharmacology and functional role of the plasma membrane dopamine transporter. 2006 , 5, 45-56	55
388	Immunological demonstration of tau protein in neurofibrillary tangles of Alzheimer's disease. <i>Journal of Alzheimers Disease</i> , 2006 , 9, 177-85	4.3 26

387	GSK-3 is essential in the pathogenesis of Alzheimer's disease. <i>Journal of Alzheimerts Disease</i> , 2006 , 9, 309-17	4-3	300
386	The Crystal Structures of Glycogen Synthase Kinase 3. 61-82		
385	KinaseKinase and SiteSite Interactions in the Phosphorylation of Tau by GSK-3. 83-103		
384	Tau protein, the paired helical filament and Alzheimer's disease. <i>Journal of Alzheimerts Disease</i> , 2006 , 9, 195-207	4-3	148
383	Tumor suppressor PTEN affects tau phosphorylation: deficiency in the phosphatase activity of PTEN increases aggregation of an FTDP-17 mutant Tau. 2006 , 1, 7		13
382	GSK3alpha exhibits beta-catenin and tau directed kinase activities that are modulated by Wnt. <i>European Journal of Neuroscience</i> , 2006 , 24, 3387-92	3-5	53
381	Phosphorylated protein kinases associated with neuronal and glial tau deposits in argyrophilic grain disease. 2003 , 13, 62-78		44
380	Troglitazone, a peroxisome proliferator-activated receptor-gamma agonist, decreases tau phosphorylation in CHOtau4R cells. 2006 , 98, 1068-77		44
379	A role of local signalling in the establishment and maintenance of the asymmetrical architecture of a neuron. 2007 , 101, 600-10		1
378	The ups and downs of Wnt signaling in prevalent neurological disorders. 2006 , 25, 7545-53		180
377	Molecular mechanisms of axon specification and neuronal disorders. 2006 , 1086, 116-25		49
376	GSK-3 is activated by the tyrosine kinase Pyk2 during LPA1-mediated neurite retraction. 2006 , 17, 1834-44		80
375	Tumor-suppressor PTEN affects tau phosphorylation, aggregation, and binding to microtubules. 2006 , 20, 1272-4		55
374	The roles of cyclin-dependent kinase 5 and glycogen synthase kinase 3 in tau hyperphosphorylation. 2006 , 281, 25457-65		261
373	Calcium-mediated transient phosphorylation of tau and amyloid precursor protein followed by intraneuronal amyloid-beta accumulation. 2006 , 281, 39907-14		85
372	Glycogen synthase kinase 3- and extracellular signal-regulated kinase-dependent phosphorylation of paxillin regulates cytoskeletal rearrangement. 2006 , 26, 2857-68		68
371	Microtubule affinity-regulating kinase 2 functions downstream of the PAR-3/PAR-6/atypical PKC complex in regulating hippocampal neuronal polarity. 2006 , 103, 8534-9		123
370	GSK3beta activity modifies the localization and function of presenilin 1. 2007 , 282, 15823-32		68

369	Glycogen synthase kinase-3 in neurodegeneration and neuroprotection: lessons from lithium. 2007 , 4, 21-31	51
368	Structure-based approaches in the design of GSK-3 selective inhibitors. 2007 , 8, 352-64	22
367	Cutting-edge patents in Alzheimer's disease drug discovery: anticipation of potential future treatments. 2007 , 2, 113-23	4
366	Chapter 4 Tau Protein and the Dementias. 2007 , 88-111	
365	The use of bioluminescence resonance energy transfer for the study of therapeutic targets: application to tyrosine kinase receptors. 2007 , 11, 541-56	21
364	Glycogen synthase kinase 3beta as a target for the therapy of shock and inflammation. 2007 , 27, 113-23	87
363	LTP inhibits LTD in the hippocampus via regulation of GSK3beta. 2007 , 53, 703-17	547
362	Cdk5 is involved in NFT-like tauopathy induced by transient cerebral ischemia in female rats. 2007 , 1772, 473-83	110
361	The role of GSK3 in glucose homeostasis and the development of insulin resistance. 2007 , 77 Suppl 1, S49-57	151
360	Kainate induces AKT, ERK and cdk5/GSK3beta pathway deregulation, phosphorylates tau protein in mouse hippocampus. 2007 , 50, 435-42	61
359	NGF-dependent formation of ruffles in PC12D cells required a different pathway from that for neurite outgrowth. 2007 , 51, 216-26	14
358	Phosphorylation of human microtubule-associated protein tau by protein kinases of the AGC subfamily. 2007 , 581, 2657-62	19
357	Links Between Amyloid and Tau Biology in Alzheimer's Disease and Their Cholinergic Aspects. 2007 , 597-656	2
356	Inhibition of IGF-I receptor in anchorage-independence attenuates GSK-3beta constitutive phosphorylation and compromises growth and survival of medulloblastoma cell lines. 2007 , 26, 2308-17	38
355	Neuronal apoptosis and reversible motor deficit in dominant-negative GSK-3 conditional transgenic mice. <i>EMBO Journal</i> , 2007 , 26, 2743-54	13 54
354	Neuronal polarity: from extracellular signals to intracellular mechanisms. 2007 , 8, 194-205	506
353	Increased level of active GSK-3beta in Alzheimer's disease and accumulation in argyrophilic grains and in neurones at different stages of neurofibrillary degeneration. 2007 , 33, 43-55	233
352	Kinase activities increase during the development of tauopathy in htau mice. 2007 , 103, 2256-67	57

351	Dementia: The Significance of Cerebral Metabolic Disturbances in Alzheimer's Disease. Relation to Parkinson's Disease. 2007 , 189-232	
350	RNA and protein-dependent mechanisms in tauopathies: consequences for therapeutic strategies. 2007 , 64, 1701-14	31
349	Tauopathies. 2007 , 64, 2219-33	226
348	Glycogen synthase kinase-3 (GSK3): inflammation, diseases, and therapeutics. 2007 , 32, 577-95	591
347	Molecular connexions between dementia and diabetes. 2007 , 31, 1046-63	119
346	Novel mechanisms of protein synthesis in diabetic nephropathy--role of mRNA translation. 2008 , 9, 255-66	16
345	Cyclin-dependent kinase 5 is associated with risk for Alzheimer's disease in a Dutch population-based study. 2008 , 255, 655-62	11
344	Protein kinase FA/glycogen synthase kinase-3 predominantly phosphorylates the in vivo site Thr97-Pro in brain myelin basic protein: evidence for Thr-Pro and Ser-Arg-X-X-Ser as consensus sequence motifs. 1994 , 62, 1596-603	43
343	Hypoxia/ischemia induces dephosphorylation of rat brain neuromodulin/GAP-43 in vivo. 1999 , 72, 1294-306	20
342	Protective effects of erythropoietin on tau phosphorylation induced by beta-amyloid. 2008 , 86, 3018-27	49
341	An ESI-MS/MS method for screening of small-molecule mixtures against glycogen synthase kinase-3beta (GSK-3beta). 2008 , 9, 1065-73	11
340	GSK-3 mediates the okadaic acid-induced modification of collapsin response mediator protein-2 in human SK-N-SH neuroblastoma cells. 2008 , 103, 1833-48	10
339	Novel GSK-3beta inhibitors from sequential virtual screening. 2008 , 16, 636-43	42
338	The role of GSK-3 in synaptic plasticity. <i>British Journal of Pharmacology</i> , 2008 , 153 Suppl 1, S428-37	8.6 191
337	The GSK3 hypothesis of Alzheimer's disease. 2008 , 104, 1433-9	773
336	A novel calcium-binding protein is associated with tau proteins in tauopathy. 2008 , 106, 96-106	54
335	Upregulation of GSK3beta expression in frontal and temporal cortex in ALS with cognitive impairment (ALSci). 2008 , 1196, 131-9	49
334	Dissociation of Akt/PKB and ribosomal S6 kinase signaling markers in a transgenic mouse model of Alzheimer's disease. 2008 , 29, 354-67	28

333	Biochemistry of Tau in Alzheimer's disease and related neurological disorders. 2008 , 5, 207-24	197
332	Lithium blocks ethanol-induced modulation of protein kinases in the developing brain. 2008 , 367, 597-602	28
331	PI3-K and GSK-3: Akt-ing together with microtubules. 2008 , 7, 2621-5	66
330	Argyrophilic grain disease. 2008 , 131, 1416-32	145
329	Immunohistochemical study on the distribution of glycogen synthase kinase 3alpha in the central nervous system of SOD1(G93A) transgenic mice. 2008 , 30, 926-31	4
328	GSK3beta: a master switch and a promising target. 2008 , 12, 1443-55	29
327	Proline-directed pseudo-phosphorylation at AT8 and PHF1 epitopes induces a compaction of the paperclip folding of Tau and generates a pathological (MC-1) conformation. 2008 , 283, 32066-76	162
326	Glycogen synthase kinase (GSK) 3beta directly phosphorylates Serine 212 in the regulatory loop and inhibits microtubule affinity-regulating kinase (MARK) 2. 2008 , 283, 18873-82	67
325	Phosphorylation regulates tau interactions with Src homology 3 domains of phosphatidylinositol 3-kinase, phospholipase Cgamma1, Grb2, and Src family kinases. 2008 , 283, 18177-86	166
324	Phosphorylation of tau regulates its axonal transport by controlling its binding to kinesin. 2008 , 22, 3186-95	124
323	Processing of amyloid precursor protein and amyloid peptide neurotoxicity. 2008 , 5, 92-9	50
322	Glycogen synthase kinase 3beta is a novel regulator of high glucose- and high insulin-induced extracellular matrix protein synthesis in renal proximal tubular epithelial cells. 2008 , 283, 30566-75	56
321	GSK-3beta is required for memory reconsolidation in adult brain. 2008 , 3, e3540	107
320	La maladie d'Alzheimer : aspects cellulaires et moléculaires. 2008 , 192, 323-332	0
319	Increasing Cu bioavailability inhibits Abeta oligomers and tau phosphorylation. 2009 , 106, 381-6	227
318	The insulin-like growth factor-1 axis and its potential as a therapeutic target in central nervous system (CNS) disorders. 2009 , 9, 95-109	12
317	Glycogen-synthase kinase-3beta is decreased in peripheral blood mononuclear cells of patients with mild cognitive impairment. 2009 , 44, 370-1	14
316	GSK-3: a key player in neurodegeneration and memory. 2009 , 61, 516-21	103

315	Cytoskeletal pathologies of Alzheimer disease. 2009 , 66, 635-49		110
314	Parkin attenuates wild-type tau modification in the presence of beta-amyloid and alpha-synuclein. 2009 , 37, 25-36		17
313	Quantitation of glycogen synthase kinase-3 sensitive proteins in neuronal membrane rafts. 2009 , 9, 3022-35		8
312	Tau pathophysiology in neurodegeneration: a tangled issue. 2009 , 32, 150-9		243
311	Knock-out and transgenic mouse models of tauopathies. 2009 , 30, 1-13		81
310	The JNK pathway amplifies and drives subcellular changes in tau phosphorylation. 2009 , 57, 539-50		46
309	Abnormalities in brain structure and behavior in GSK-3alpha mutant mice. 2009 , 2, 35		138
308	Mediators of tau phosphorylation in the pathogenesis of Alzheimer's disease. 2009 , 9, 1647-66		71
307	PTEN and PI3 Kinase Signaling in the Nervous System. 2009 , 245-267		
306	The insulin-like growth factor family: molecular mechanisms, redox regulation, and clinical implications. 2009 , 11, 1165-90		48
305	The microtubule-associated protein tau is also phosphorylated on tyrosine. <i>Journal of Alzheimerts Disease</i> , 2009 , 18, 1-9	4-3	57
304	Drug development targeting the glycogen synthase kinase-3beta (GSK-3beta)-mediated signal transduction pathway: role of GSK-3beta in adult brain. 2009 , 109, 174-8		30
303	Functional implications of the association of tau with the plasma membrane. 2010 , 38, 1012-5		47
302	Okadaic acid induces tau phosphorylation in SH-SY5Y cells in an estrogen-preventable manner. 2010 , 1345, 176-81		48
301	An okadaic acid-induced model of tauopathy and cognitive deficiency. 2010 , 1359, 233-46		54
300	GSK3beta: role in therapeutic landscape and development of modulators. <i>British Journal of Pharmacology</i> , 2010 , 160, 1-19	8.6	109
299	Amyloid regulates leptin expression and tau phosphorylation through the mTORC1 signaling pathway. 2010 , 115, 373-84		29
298	Role of Glycogen Synthase Kinase-3 In APP Hyperphosphorylation Induced by NMDA Stimulation in Cortical Neurons. 2010 , 3, 42-58		4

297	Inhibition of GSK-3 ameliorates Abeta pathology in an adult-onset Drosophila model of Alzheimer's disease. 2010 , 6, e1001087	118
296	Spectroscopic studies of GSK3{beta} phosphorylation of the neuronal tau protein and its interaction with the N-terminal domain of apolipoprotein E. 2010 , 285, 33435-33444	52
295	Tau cleavage and tau aggregation in neurodegenerative disease. 2010 , 38, 1016-20	43
294	Insulin regulates Presenilin 1 localization via PI3K/Akt signaling. <i>Neuroscience Letters</i> , 2010 , 483, 157-61 3,3	9
293	Animal models reveal role for tau phosphorylation in human disease. 2010 , 1802, 860-71	63
292	Inhibition of phospholipase A2 increases tau phosphorylation at Ser214 in embryonic rat hippocampal neurons. 2010 , 82, 57-60	10
291	Icariin attenuates Amyloid-induced neurotoxicity by inhibition of tau protein hyperphosphorylation in PC12 cells. 2010 , 59, 542-50	81
290	Diabetes, Insulin and Alzheimer's Disease. <i>Research and Perspectives in Alzheimerts Disease</i> , 2010 ,	2
289	Identification of O-GlcNAc sites within peptides of the Tau protein and their impact on phosphorylation. 2011 , 7, 1420-9	91
288	Tau Pathology. 2011 , 83-132	1
287	Protein Folding, Misfolding, and Disease. 2011 ,	0
286	Potential of tau aggregation by cdk5 and GSK3 \square <i>Journal of Alzheimerts Disease</i> , 2011 , 26, 355-64	4.3 20
285	Aroclor1254 interferes with estrogen receptor-mediated neuroprotection against beta-amyloid toxicity in cholinergic SN56 cells. 2011 , 59, 582-90	6
284	Effect of glycogen synthase kinase 3 \square mediated presenilin 1 phosphorylation on amyloid \square production is negatively regulated by insulin receptor cleavage. 2011 , 177, 298-307	16
283	Functional implications of glycogen synthase kinase-3-mediated tau phosphorylation. 2011 , 2011, 352805	66
282	The role of tau in Alzheimer's disease and related disorders. 2011 , 17, 514-24	95
281	Calpain-mediated tau cleavage: a mechanism leading to neurodegeneration shared by multiple tauopathies. 2011 , 17, 676-85	75
280	Insulin Resistance and Alzheimer's Disease. 2011 ,	1

279	GSK-3 in Neurodegenerative Diseases. 2011 , 2011, 189246		96
278	What Are the bona fide GSK3 Substrates?. 2011 , 2011, 505607		207
277	Increased mRNA Levels of TCF7L2 and MYC of the Wnt Pathway in Tg-ArcSwe Mice and Alzheimer's Disease Brain. 2010 , 2011, 936580		5
276	Deconstructing GSK-3: The Fine Regulation of Its Activity. 2011 , 2011, 479249		97
275	Modulation of GSK-3 as a Therapeutic Strategy on Tau Pathologies. 2011 , 4, 24		76
274	GSK-3: Functional Insights from Cell Biology and Animal Models. 2011 , 4, 40		313
273	WNT5A signaling contributes to A β -induced neuroinflammation and neurotoxicity. 2011 , 6, e22920		55
272	Transcriptomic profiles of Wnt3a and insulin in primary cultured rat cortical neurones. 2011 , 118, 512-20		6
271	The Alzheimer's therapeutic PBT2 promotes amyloid- β degradation and GSK3 phosphorylation via a metal chaperone activity. 2011 , 119, 220-30		142
270	Sildenafil restores cognitive function without affecting β amyloid burden in a mouse model of Alzheimer's disease. <i>British Journal of Pharmacology</i> , 2011 , 164, 2029-41	8.6	129
269	Stimulatory effect of β synuclein on the tau-phosphorylation by GSK-3 β 2011 , 278, 4895-904		57
268	Selective loss of glycogen synthase kinase-3 β in birds reveals distinct roles for GSK-3 isozymes in tau phosphorylation. 2011 , 585, 1158-62		34
267	Neuroprotective effects of linarin through activation of the PI3K/Akt pathway in amyloid- β -induced neuronal cell death. 2011 , 19, 4021-7		101
266	Pathogenesis of the tauopathies. 2011 , 45, 425-31		93
265	Huntington's disease and Group I metabotropic glutamate receptors. 2011 , 43, 1-11		38
264	Interplay between glycogen synthase kinase-3 β and tau in the cerebellum of Hsp27 transgenic mouse. 2011 , 89, 1267-75		8
263	High fluence low-power laser irradiation induces apoptosis via inactivation of Akt/GSK3 β signaling pathway. 2011 , 226, 588-601		51
262	A role for calcineurin in Alzheimer's disease. <i>Current Neuropharmacology</i> , 2011 , 9, 685-92	7.6	74

261	Citrus flavonoids luteolin, apigenin, and quercetin inhibit glycogen synthase kinase-3 β enzymatic activity by lowering the interaction energy within the binding cavity. 2011 , 14, 325-33		82
260	Functional genomic screen and network analysis reveal novel modifiers of tauopathy dissociated from tau phosphorylation. 2011 , 20, 4947-77		78
259	Local application of neurotrophins specifies axons through inositol 1,4,5-trisphosphate, calcium, and Ca ²⁺ /calmodulin-dependent protein kinases. <i>Science Signaling</i> , 2011 , 4, ra76	8.8	43
258	MMFPh: a maximal motif finder for phosphoproteomics datasets. 2012 , 28, 1562-70		26
257	Effects of ginkgolide A on okadaic acid-induced tau hyperphosphorylation and the PI3K-Akt signaling pathway in N2a cells. 2012 , 78, 1337-41		26
256	Identification of oligomers at early stages of tau aggregation in Alzheimer's disease. 2012 , 26, 1946-59		309
255	Neurological functions of the masterswitch protein kinase - gsk-3. 2012 , 5, 48		19
254	Lithium treatment of APPSwDI/NOS2 ^{-/-} mice leads to reduced hyperphosphorylated tau, increased amyloid deposition and altered inflammatory phenotype. 2012 , 7, e31993		32
253	Evidence for irreversible inhibition of glycogen synthase kinase-3 β by tideglusib. 2012 , 287, 893-904		148
252	Trait, state, and mechanism: looking back, looking forward, and understanding why. <i>Journal of Alzheimers Disease</i> , 2013 , 33 Suppl 1, S23-33	4.3	1
251	Biochemistry and cell biology of tau protein in neurofibrillary degeneration. 2012 , 2, a006247		463
250	Dynamic association of tau with neuronal membranes is regulated by phosphorylation. 2012 , 33, 431.e27-38		95
249	Gain of function by phosphorylation in Presenilin 1-mediated regulation of insulin signaling. 2012 , 121, 964-73		8
248	Mitotic and mitogenic Wnt signalling. <i>EMBO Journal</i> , 2012 , 31, 2705-13	13	204
247	Chronic peripheral hyperinsulinemia has no substantial influence on tau phosphorylation in vivo. <i>Neuroscience Letters</i> , 2012 , 516, 306-10	3.3	18
246	The peripheral messenger RNA expression of glycogen synthase kinase-3 β genes in Alzheimer's disease patients: a preliminary study. 2012 , 12, 248-54		2
245	Therapeutic redistribution of metal ions to treat Alzheimer's disease. 2012 , 45, 1604-11		97
244	Identification of novel scaffold of benzothiazepinones as non-ATP competitive glycogen synthase kinase-3 β inhibitors through virtual screening. 2012 , 22, 7232-6		14

243	Coordinating Gene Expression and Axon Assembly to Control Axon Growth: Potential Role of GSK3 Signaling. 2012 , 5, 3	27
242	GSK3 as a Sensor Determining Cell Fate in the Brain. 2012 , 5, 4	57
241	Neuropathogenic role of adenylate kinase-1 in A β -mediated tau phosphorylation via AMPK and GSK3 β . 2012 , 21, 2725-37	61
240	Cellular model of Alzheimer's disease--relevance to therapeutic testing. 2012 , 233, 733-9	6
239	PTEN: A molecular target for neurodegenerative disorders. 2012 , 3,	9
238	Flavonoids as lead compounds modulating the enzyme targets in Alzheimer's disease. 2013 , 22, 3061-3075	21
237	1,4-Substituted 4-(1H)-pyridylene-hydrazone-type inhibitors of AChE, BuChE, and amyloid- β aggregation crossing the blood-brain barrier. 2013 , 49, 603-13	22
236	Viewpoint: Crosstalks between neurofibrillary tangles and amyloid plaque formation. 2013 , 12, 174-81	28
235	Phosphorylation of threonine-19 of PSD-95 by GSK-3 β s required for PSD-95 mobilization and long-term depression. 2013 , 33, 12122-35	84
234	Obesity promotes liver carcinogenesis via Mcl-1 stabilization independent of IL-6R α signaling. 2013 , 4, 669-80	25
233	The Importance of Olfactory and Motor Endpoints for Zebrafish Models of Neurodegenerative Disease. 2013 , 651-678	
232	Influence of PKG on insulin signalling and GSK3 phosphorylation in SH-SY5Y cells. 2013 , 14,	1
231	Beyond Secretases. 2013 , 48, 57-71	2
230	A novel functional low-density lipoprotein receptor-related protein 6 gene alternative splice variant is associated with Alzheimer's disease. 2013 , 34, 1709.e9-18	27
229	Therapeutic potential of mood stabilizers lithium and valproic acid: beyond bipolar disorder. 2013 , 65, 105-42	293
228	AZD1080, a novel GSK3 inhibitor, rescues synaptic plasticity deficits in rodent brain and exhibits peripheral target engagement in humans. 2013 , 125, 446-56	62
227	Mifepristone alters amyloid precursor protein processing to preclude amyloid beta and also reduces tau pathology. 2013 , 74, 357-66	73
226	Unfolded protein response activates glycogen synthase kinase-3 via selective lysosomal degradation. 2013 , 34, 1759-71	37

225	Reelin signaling in development, maintenance, and plasticity of neural networks. 2013 , 12, 815-22	55
224	Global analysis of phosphorylation of tau by the checkpoint kinases Chk1 and Chk2 in vitro. 2013 , 12, 2654-65	29
223	Activator or inhibitor? GSK-3 as a new drug target. 2013 , 86, 191-9	137
222	Involvement of GSK3 and PP2A in ginsenoside Rb1's attenuation of aluminum-induced tau hyperphosphorylation. 2013 , 241, 228-34	40
221	Electrochemical investigations into kinase-catalyzed transformations of tau protein. 2013 , 4, 1194-203	20
220	Tadalafil crosses the blood-brain barrier and reverses cognitive dysfunction in a mouse model of AD. 2013 , 64, 114-23	109
219	Glycogen synthase kinase-3[[GSK3]] expression in a mouse model of Alzheimer's disease: a light and electron microscopy study. 2013 , 67, 313-27	11
218	Design of glycogen synthase kinase-3 inhibitors: an overview on recent advancements. 2013 , 19, 4755-75	25
217	Glycogen synthase kinase 3 substrates in mood disorders and schizophrenia. 2013 , 280, 5213-27	47
216	The importance of tau phosphorylation for neurodegenerative diseases. 2013 , 4, 83	207
215	The Role of Glycogen Synthase Kinase 3 Beta in Neuroinflammation and Pain. 2013 , 1, 001	35
214	Alpha 1-Antichymotrypsin, an Inflammatory Protein Overexpressed in the Brains of Patients with Alzheimer's Disease, Induces Tau Hyperphosphorylation through c-Jun N-Terminal Kinase Activation. 2013 , 2013, 606083	24
213	The Amyloidogenic Pathway Meets the Reelin Signaling Cascade: A Cytoskeleton Bridge Between Neurodevelopment and Neurodegeneration. 2013 ,	
212	NEURONAL FUNCTIONS OF PROTEIN PHOSPHATASE 2A. 2013 , 4, 46-55	2
211	Targeting the GSK3[[GSK3]]/E-catenin Signaling to Treat Alzheimer's Disease: Plausible or Utopic?. 2014 , 623-642	2
210	Targets and Small Molecules Against Tauopathies. Part 1: From Genes to Soluble, Aggregation-Prone Tau Proteins. 2014 , 643-715	
209	Modification of the Drosophila model of in vivo Tau toxicity reveals protective phosphorylation by GSK3[[GSK3]]. 2014 , 3, 1-11	20
208	Presenilin influences glycogen synthase kinase-3 [[GSK-3]] for kinesin-1 and dynein function during axonal transport. 2014 , 23, 1121-33	33

207	The spleen tyrosine kinase (Syk) regulates Alzheimer amyloid- β production and Tau hyperphosphorylation. 2014 , 289, 33927-44		44
206	Platelets, a reliable source for peripheral Alzheimer's disease biomarkers?. 2014 , 2, 65		54
205	Antisense oligonucleotide against GSK-3 β in brain of SAMP8 mice improves learning and memory and decreases oxidative stress: Involvement of transcription factor Nrf2 and implications for Alzheimer disease. 2014 , 67, 387-95		95
204	Abnormal serine phosphorylation of insulin receptor substrate 1 is associated with tau pathology in Alzheimer's disease and tauopathies. 2014 , 128, 679-89		127
203	The potential therapeutic effects of THC on Alzheimer's disease. <i>Journal of Alzheimerts Disease</i> , 2014 , 42, 973-84	4-3	53
202	Microtubule-associated protein tau is essential for long-term depression in the hippocampus. 2014 , 369, 20130144		176
201	Overstimulation can create health problems due to increases in PI3K/Akt/GSK3 insensitivity and GSK3 activity. 2014 , 3, 356		15
200	Localized changes to glycogen synthase kinase-3 and collapsin response mediator protein-2 in the Huntington's disease affected brain. 2014 , 23, 4051-63		36
199	Is amyloid- β an innocent bystander and marker in Alzheimer's disease? Is the liability of multivalent cation homeostasis and its influence on amyloid- β function the real mechanism?. <i>Journal of Alzheimerts Disease</i> , 2014 , 42, 69-85	4-3	11
198	Environmental factors in the development and progression of late-onset Alzheimer's disease. 2014 , 30, 253-70		25
197	Exploring structural requirements of leads for improving activity and selectivity against CDK5/p25 in Alzheimer's disease: an in silico approach. 2014 , 4, 6702-6709		20
196	Subcellular targeting and dynamic regulation of PTEN: implications for neuronal cells and neurological disorders. 2014 , 7, 23		58
195	Activation of the 5'-AMP-Activated Protein Kinase in the Cerebral Cortex of Young Senescence-Accelerated P8 Mice and Association with GSK3 β and PP2A-Dependent Inhibition of p-tau Expression. <i>Journal of Alzheimerts Disease</i> , 2015 , 46, 249-59	4-3	21
194	Rescue from tau-induced neuronal dysfunction produces insoluble tau oligomers. 2015 , 5, 17191		25
193	Valproic Acid Modifies Synaptic Structure and Accelerates Neurite Outgrowth Via the Glycogen Synthase Kinase-3 β Signaling Pathway in an Alzheimer's Disease Model. 2015 , 21, 887-97		31
192	The roles of lipid and glucose metabolism in modulation of β amyloid, tau, and neurodegeneration in the pathogenesis of Alzheimer disease. 2015 , 7, 199		107
191	The 5-lipoxygenase pathway: oxidative and inflammatory contributions to the Alzheimer's disease phenotype. 2014 , 8, 436		49
190	Cellular factors modulating the mechanism of tau protein aggregation. 2015 , 72, 1863-79		42

189	Transcription factor IKZF1 is degraded during the apoptosis of multiple myeloma cells induced by kinase inhibition. 2015 , 589, 2233-40		6
188	The 12/15-lipoxygenase as an emerging therapeutic target for Alzheimer's disease. 2015 , 36, 181-186		44
187	Studying tauopathies in Drosophila: A fruitful model. 2015 , 274, 52-7		21
186	Acute decrease in alkaline phosphatase after brain injury: A potential mechanism for tauopathy. <i>Neuroscience Letters</i> , 2015 , 609, 152-8	3-3	19
185	Hit Optimization of 5-Substituted-N-(piperidin-4-ylmethyl)-1H-indazole-3-carboxamides: Potent Glycogen Synthase Kinase-3 (GSK-3) Inhibitors with in Vivo Activity in Model of Mood Disorders. 2015 , 58, 8920-37		24
184	Multiple alternative splicing and differential expression patterns of the glycogen synthase kinase-3[GSK3]gene in Schizothorax prenanti. 2015 , 181, 1-6		4
183	Glycogen synthase kinase-3 (GSK3): regulation, actions, and diseases. 2015 , 148, 114-31		821
182	Quantitative phosphoproteomics of Alzheimer's disease reveals cross-talk between kinases and small heat shock proteins. 2015 , 15, 508-519		48
181	Diabetes Mellitus Induces Alzheimer's Disease Pathology: Histopathological Evidence from Animal Models. <i>International Journal of Molecular Sciences</i> , 2016 , 17, 503	6-3	61
180	Glycogen synthase kinase 3β suppresses polyglutamine aggregation by inhibiting Vaccinia-related kinase 2 activity. 2016 , 6, 29097		9
179	Fibrillar Amyloid-β Accumulation Triggers an Inflammatory Mechanism Leading to Hyperphosphorylation of the Carboxyl-Terminal End of Tau Polypeptide in the Hippocampal Formation of the 3Tg-AD Transgenic Mouse. <i>Journal of Alzheimerts Disease</i> , 2016 , 52, 243-69	4-3	14
178	A cAMP and CREB-mediated feed-forward mechanism regulates GSK3β in polycystic kidney disease. 2016 , 8, 464-476		12
177	GSK-3β Induced Tau pathology drives hippocampal neuronal cell death in Huntington's disease: involvement of astrocyte-neuron interactions. 2016 , 7, e2206		40
176	Loss of Endothelial Nitric Oxide Synthase Promotes p25 Generation and Tau Phosphorylation in a Murine Model of Alzheimer's Disease. 2016 , 119, 1128-1134		34
175	l-Theanine attenuates cadmium-induced neurotoxicity through the inhibition of oxidative damage and tau hyperphosphorylation. 2016 , 57, 95-103		39
174	Tau and tauopathies. 2016 , 126, 238-292		292
173	The Tyr216 phosphorylated form of GSK3β contributes to tau phosphorylation at PHF-1 epitope in response to Aβ in the nucleus of SH-SY5Y cells. 2016 , 158, 14-21		11
172	A unique type of GSK-3 inhibitor brings new opportunities to the clinic. <i>Science Signaling</i> , 2016 , 9, ra110 8.8		46

171	Pyrrrolidine dithiocarbamate activates the Nrf2 pathway in astrocytes. 2016 , 13, 49	27
170	Regulation of mitochondrial functions by protein phosphorylation and dephosphorylation. 2016 , 6, 25	60
169	Tauopathy induced by low level expression of a human brain-derived tau fragment in mice is rescued by phenylbutyrate. 2016 , 139, 2290-306	28
168	Evidence for an imbalance between tau O-GlcNAcylation and phosphorylation in the hippocampus of a mouse model of Alzheimer's disease. 2016 , 105, 186-97	33
167	Nuclear spheres modulate the expression of BEST1 and GADD45G. 2016 , 28, 100-9	5
166	The rise and fall of insulin signaling in Alzheimer's disease. 2016 , 31, 497-515	33
165	E-pharmacophore-based virtual screening to identify GSK-3 β inhibitors. 2016 , 36, 445-58	19
164	Reduced number of axonal mitochondria and tau hypophosphorylation in mouse P301L tau knockin neurons. 2016 , 85, 1-10	40
163	Pivotal role of glycogen synthase kinase-3: A therapeutic target for Alzheimer's disease. 2016 , 107, 63-81	145
162	Impact of Phosphorylation and Pseudophosphorylation on the Early Stages of Aggregation of the Microtubule-Associated Protein Tau. 2017 , 121, 2095-2103	10
161	Small things matter: Implications of APP intracellular domain AICD nuclear signaling in the progression and pathogenesis of Alzheimer's disease. 2017 , 156, 189-213	33
160	The use of cerebrospinal fluid biomarkers to measure change in neurodegeneration in Alzheimer's disease clinical trials. 2017 , 17, 767-775	4
159	Roles of tau protein in health and disease. 2017 , 133, 665-704	415
158	Dickkopf 3 (Dkk3) Improves Amyloid- β Pathology, Cognitive Dysfunction, and Cerebral Glucose Metabolism in a Transgenic Mouse Model of Alzheimer's Disease. <i>Journal of Alzheimers Disease</i> , 2017 , 60, 733-746	4-3 7
157	Benzisoxazole: a privileged scaffold for medicinal chemistry. 2017 , 8, 2023-2039	42
156	Pazopanib Reduces Phosphorylated Tau Levels and Alters Astrocytes in a Mouse Model of Tauopathy. <i>Journal of Alzheimers Disease</i> , 2017 , 60, 461-481	4-3 12
155	Inhibition of glycogen synthase kinase-3 by BTA-EG reduces tau abnormalities in an organotypic brain slice culture model of Alzheimer's disease. 2017 , 7, 7434	16
154	Lithium and valproate act on the GSK-3 β signaling pathway to reverse manic-like behavior in an animal model of mania induced by ouabain. 2017 , 117, 447-459	27

153	Natural and synthetic bioactive inhibitors of glycogen synthase kinase. 2017 , 125, 464-477		49
152	Rab-GTPase binding effector protein 2 (RABEP2) is a primed substrate for Glycogen Synthase kinase-3 (GSK3). 2017 , 7, 17682		4
151	The Role of NO/cGMP Signaling on Neuroinflammation: A New Therapeutic Opportunity. 2017 ,		3
150	The Importance of Olfactory and Motor Endpoints for Zebrafish Models of Neurodegenerative Disease. 2017 , 525-554		1
149	Activation of Ras-ERK Signaling and GSK-3 by Amyloid Precursor Protein and Amyloid Beta Facilitates Neurodegeneration in Alzheimer's Disease. 2017 , 4,		94
148	An overview of the possible therapeutic role of SUMOylation in the treatment of Alzheimer's disease. 2018 , 130, 420-437		11
147	Tau Proteins and Tauopathies in Alzheimer's Disease. 2018 , 38, 965-980		109
146	Cognitive benefits of lithium chloride in APP/PS1 mice are associated with enhanced brain clearance of β amyloid. 2018 , 70, 36-47		21
145	A partnership with the proteasome; the destructive nature of GSK3. 2018 , 147, 77-92		46
144	Recent Advances in Computational Approaches for Designing Potential Anti-Alzheimer's Agents. <i>Neuromethods</i> , 2018 , 25-59	0.4	2
143	Diabetes mellitus and Alzheimer's disease: GSK-3 β as a potential link. 2018 , 339, 57-65		110
142	Myotonic Dystrophy. 2018 ,		1
141	Molecular Defects in the DM Central Nervous System. 2018 , 115-131		
140	Bi-directional genetic modulation of GSK-3 β exacerbates hippocampal neuropathology in experimental status epilepticus. 2018 , 9, 969		16
139	Targeting GSK3 signaling as a potential therapy of neurodegenerative diseases and aging. 2018 , 22, 833-848		52
138	Molecular mechanism of diabetic neuropathy and its pharmacotherapeutic targets. 2018 , 833, 472-523		95
137	Asiatic acid protects differentiated PC12 cells from A β -induced apoptosis and tau hyperphosphorylation via regulating PI3K/Akt/GSK-3 β signaling. 2018 , 208, 96-101		26
136	Tau-Induced Pathology in Epilepsy and Dementia: Notions from Patients and Animal Models. <i>International Journal of Molecular Sciences</i> , 2018 , 19,	6.3	33

135	A new TAO kinase inhibitor reduces tau phosphorylation at sites associated with neurodegeneration in human tauopathies. 2018 , 6, 37	26
134	Inhibition of GSK-3β in Behavioral Changes and Oxidative Stress in an Animal Model of Mania. 2019 , 56, 2379-2393	12
133	WNT Signaling in Disease. 2019 , 8,	95
132	An expanding GSK3 network: implications for aging research. 2019 , 41, 369-382	30
131	Association of PPP2R1A with Alzheimer's disease and specific cognitive domains. 2019 , 81, 234-243	8
130	Allosteric Modulators of Potential Targets Related to Alzheimer's Disease: a Review. 2019 , 14, 1467-1483	3
129	Structural characterization of monoclonal antibodies targeting C-terminal Ser region of phosphorylated tau protein. 2019 , 11, 477-488	6
128	Structural Basis for Achieving GSK-3β Inhibition with High Potency, Selectivity, and Brain Exposure for Positron Emission Tomography Imaging and Drug Discovery. 2019 , 62, 9600-9617	19
127	Stress granules and neurodegeneration. 2019 , 20, 649-666	189
126	Four-repeat tauopathies. 2019 , 180, 101644	77
125	Alzheimer's Disease Associated Genes Ankyrin and Tau Cause Shortened Lifespan and Memory Loss in. 2019 , 13, 260	21
124	GSK-3 at the Intersection of Neuronal Plasticity and Neurodegeneration. 2019 , 2019, 4209475	41
123	DRG2 knockdown induces Golgi fragmentation via GSK3β phosphorylation and microtubule stabilization. 2019 , 1866, 1463-1474	5
122	Regulation of neuronal microtubule dynamics by tau: Implications for tauopathies. 2019 , 133, 473-483	25
121	Major Differences between the Self-Assembly and Seeding Behavior of Heparin-Induced and in Vitro Phosphorylated Tau and Their Modulation by Potential Inhibitors. 2019 , 14, 1363-1379	21
120	Synthesis and evaluation of novel GSK-3β inhibitors as multifunctional agents against Alzheimer's disease. 2019 , 167, 211-225	23
119	rAAV-based brain slice culture models of Alzheimer's and Parkinson's disease inclusion pathologies. 2019 , 216, 539-555	22
118	Involvement of calpain in the neuropathogenesis of Alzheimer's disease. 2019 , 39, 608-630	31

117	Timing Matters: Circadian Effects on Energy Homeostasis and Alzheimer's Disease. 2019 , 30, 132-143	6
116	Alzheimer's Disease and Dementia. 2019 , 25-82	0
115	Lithium chloride promotes lipid accumulation through increased reactive oxygen species generation. 2020 , 1865, 158552	7
114	The role of mitochondria-associated membranes in cellular homeostasis and diseases. 2020 , 350, 119-196	32
113	Global quantitative analysis of the human brain proteome and phosphoproteome in Alzheimer's disease. 2020 , 7, 315	14
112	Microglia in Alzheimer's Disease in the Context of Tau Pathology. 2020 , 10,	22
111	Machine Learning for Discovery of GSK3 β Inhibitors. 2020 , 5, 26551-26561	10
110	Clinically Precedented Protein Kinases: Rationale for Their Use in Neurodegenerative Disease. 2020 , 12, 242	8
109	Fyn depletion ameliorates tau-induced neuropathology. 2020 , 8, 108	6
108	Galectin-3 Secreted by Human Umbilical Cord Blood-Derived Mesenchymal Stem Cells Reduces Aberrant Tau Phosphorylation in an Alzheimer Disease Model. 2020 , 2020, 8878412	7
107	Avenanthramide C Prevents Neuronal Apoptosis via PI3K/Akt/GSK3 β Signaling Pathway Following Middle Cerebral Artery Occlusion. 2020 , 10,	7
106	Discovery and Design of Novel Small Molecule GSK-3 Inhibitors Targeting the Substrate Binding Site. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3 9
105	MiR-9-5p inhibits mitochondrial damage and oxidative stress in AD cell models by targeting GSK-3 β 2020 , 84, 2273-2280	9
104	Unravelling the Role of Glycogen Synthase Kinase-3 in Alzheimer's Disease-Related Epileptic Seizures. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3 7
103	DNA methylation in the pathology of Alzheimer's disease: from gene to cognition. 2020 , 1475, 15-33	6
102	NRF2 Regulation Processes as a Source of Potential Drug Targets against Neurodegenerative Diseases. 2020 , 10,	23
101	Neuropathological Mechanisms Associated with Pesticides in Alzheimer's Disease. 2020 , 8,	14
100	Modulators of calpain activity: inhibitors and activators as potential drugs. 2020 , 15, 471-486	6

99	A systematic review on anti-Alzheimer's disease activity of prescription Kangen-karyu. 2020 , 14, 61-66	2
98	Meridianins and Lignarenone B as Potential GSK3β Inhibitors and Inducers of Structural Neuronal Plasticity. 2020 , 10,	9
97	Flavonoids as an Intervention for Alzheimer's Disease: Progress and Hurdles Towards Defining a Mechanism of Action. 2021 , 6, 167-192	11
96	Glycogen Synthase Kinase 3β A New Gold Rush in Anti-Alzheimer's Disease Multitarget Drug Discovery?. 2021 , 64, 26-41	15
95	Human Dental Pulp Stem Cells Display a Potential for Modeling Alzheimer Disease-Related Tau Modifications. 2020 , 11, 612657	
94	Isoform-selective decrease of glycogen synthase kinase-3-beta (GSK-3β) reduces synaptic tau phosphorylation, transcellular spreading, and aggregation. 2021 , 24, 102058	7
93	Role of insulin receptor substance-1 modulating PI3K/Akt insulin signaling pathway in Alzheimer's disease. 2021 , 11, 179	2
92	GSK-3 and Tau: A Key Duet in Alzheimer's Disease. 2021 , 10,	26
91	Lower insulin secretion is associated with hippocampal and parahippocampal gyrus atrophy in elderly patients with type 2 diabetes mellitus. 2021 , 12, 1908-1913	3
90	Intranasal insulin and orexins to treat age-related cognitive decline. 2021 , 234, 113370	7
89	Insulin Resistance as a Common Link Between Current Alzheimer's Disease Hypotheses. <i>Journal of Alzheimerts Disease</i> , 2021 , 82, 71-105	4-3 7
88	N-terminal phosphorylation regulates the activity of Glycogen Synthase Kinase 3 from Plasmodium falciparum.	
87	Phosphorylation and -GlcNAcylation of the PHF-1 Epitope of Tau Protein Induce Local Conformational Changes of the C-Terminus and Modulate Tau Self-Assembly Into Fibrillar Aggregates. 2021 , 14, 661368	5
86	Downregulation of glob1 suppresses pathogenesis of human neuronal tauopathies in Drosophila by regulating tau phosphorylation and ROS generation. 2021 , 146, 105040	0
85	Protection of Beta Boswellic Acid against Streptozotocin-induced Alzheimer's Model by Reduction of Tau Phosphorylation Level and Enhancement of Reelin Expression. 2021 ,	1
84	Diabetic Neuropathy: Review on Molecular Mechanisms. 2021 ,	0
83	Tau Protein Interaction Partners and Their Roles in Alzheimer's Disease and Other Tauopathies. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6-3 7
82	Proteome-Wide Characterizations of -Methyl-Adenosine Triphosphate- and -Furfuryl-Adenosine Triphosphate-Binding Capabilities of Kinases. 2021 , 93, 13251-13259	0

81	Recent advances in drug repurposing using machine learning. 2021 , 65, 74-84	5
80	Effect of alcohol on the central nervous system to develop neurological disorder: pathophysiological and lifestyle modulation can be potential therapeutic options for alcohol-induced neurotoxication. 2021 , 8, 390-413	1
79	Deregulation of Cytoskeletal Protein Phosphorylation and Neurodegeneration. 2011 , 297-324	2
78	Influence of phospholipids and sequential kinase activities on tau in vitro. 1998 , 446, 181-201	2
77	Molecular Pathology of Alzheimer's Disease and Related Disorders. 1999 , 603-654	18
76	Elucidating the role of metals in Alzheimer's disease through the use of Surface-Enhanced Laser Desorption/Ionisation time-of-flight mass spectrometry. 2011 , 752, 229-40	2
75	GSK-3 Inhibitors: From the Brain to the Retina and Back Again. 2019 , 1185, 437-441	4
74	Is Alzheimer's a Disorder of Ageing and Why Don't Mice get it? The Centrality of Insulin Signalling to Alzheimer's Disease Pathology. <i>Research and Perspectives in Alzheimerts Disease</i> , 2010 , 129-152	1
73	Tau Variants in Aging and Neurodegenerative Disorders. 1995 , 132-149	2
72	Linking Amyloid Precursor Protein Processing and Tau-Related Pathology in Alzheimer's Disease. 1995 , 230-240	1
71	Neurodegenerative Disorders with Tauopathies: Mad Tau Diseases?. <i>Research and Perspectives in Alzheimerts Disease</i> , 2000 , 105-125	1
70	Structure, biochemistry and molecular pathogenesis of paired helical filaments in Alzheimer's disease. 1995 , 9-11	4
69	Tau proteins and their significance in the pathobiology of Alzheimer's disease. 1995 , 41-58	4
68	Microtubule-Associated Protein Tau. 1998 , 153-169	3
67	Okadaic acid, a serine/threonine phosphatase inhibitor, induces tyrosine dephosphorylation/inactivation of protein kinase FA/GSK-3 alpha in A431 cells.. 1994 , 269, 14341-14344	26
66	Glycogen synthase kinase-3 beta is a dual specificity kinase differentially regulated by tyrosine and serine/threonine phosphorylation.. 1994 , 269, 14566-14574	214
65	The phosphorylation state of tau in the developing rat brain is regulated by phosphoprotein phosphatases.. 1994 , 269, 30981-30987	106
64	Role of Dopamine Transporters in Neuronal Homeostasis. 2009 , 88-99	2

63	Global quantitative analysis of the human brain proteome and phosphoproteome in Alzheimer's disease.		1
62	Cellular phosphorylation of tau by GSK-3 beta influences tau binding to microtubules and microtubule organisation. 1996 , 109, 1537-1543		179
61	Light and electron microscopy study of glycogen synthase kinase-3beta in the mouse brain. 2010 , 5, e8911		42
60	Efficacy and safety of a liposome-based vaccine against protein Tau, assessed in tau.P301L mice that model tauopathy. 2013 , 8, e72301		159
59	Knockout of p75 neurotrophin receptor attenuates the hyperphosphorylation of Tau in pR5 mouse model. <i>Aging</i> , 2019 , 11, 6762-6791	5.6	13
58	PERK-opathies: An Endoplasmic Reticulum Stress Mechanism Underlying Neurodegeneration. 2016 , 13, 150-63		43
57	Curcumin and its derivatives: their application in neuropharmacology and neuroscience in the 21st century. <i>Current Neuropharmacology</i> , 2013 , 11, 338-78	7.6	313
56	Molecular Mechanism of Autophagy: Its Role in the Therapy of Alzheimer's Disease. <i>Current Neuropharmacology</i> , 2020 , 18, 720-739	7.6	10
55	Regulation of glycogen synthase kinase 3beta functions by modification of the small ubiquitin-like modifier. <i>The Open Biochemistry Journal</i> , 2008 , 2, 67-76	0.9	19
54	Is There Justification to Treat Neurodegenerative Disorders by Repurposing Drugs? The Case of Alzheimer's Disease, Lithium, and Autophagy. <i>International Journal of Molecular Sciences</i> , 2020 , 22,	6.3	9
53	Phosphorylation of tau protein over time in rats subjected to transient brain ischemia. <i>Neural Regeneration Research</i> , 2013 , 8, 3173-82	4.5	19
52	Indirubin-3'-monoxime suppresses amyloid-beta-induced apoptosis by inhibiting tau hyperphosphorylation. <i>Neural Regeneration Research</i> , 2016 , 11, 988-93	4.5	13
51	Molecular and biochemical trajectories from diabetes to Alzheimer's disease: A critical appraisal. <i>World Journal of Diabetes</i> , 2015 , 6, 1223-42	4.7	29
50	Distinct Tau Gene Mutations Induce Specific Dysfunctions/Toxic Properties in Tau Proteins Associated With Specific FTDP-17 Phenotypes. <i>Research and Perspectives in Alzheimers Disease</i> , 2000 , 87-104		
49	GSK-3 and Wnt Markers of Neurodevelopmental Abnormalities in Schizophrenia. <i>Neurobiological Foundation of Aberrant Behaviors</i> , 2002 , 267-276		
48	Wnt Signaling in Neurite Development. 2007 , 222-238		
47	Cdk5 and Neuregulin-1 Signaling. 2008 , 139-144		
46	TAU Models. <i>Neuromethods</i> , 2011 , 449-468	0.4	

45	Introduction to the Tauopathies. 103-109			1
44	New Small Molecule Drug Discovery for Alzheimer's Disease. <i>Frontiers in Neuroscience</i> , 2012 , 163-210			
43	Insulin Receptor and the Pathophysiology of Alzheimer Disease. 31-50			
42	Phosphorylation of Tau and Its Relationship with Alzheimer Paired Helical Filaments. 1995 , 103-120			1
41	Tau Protein and the Neurofibrillary Pathology of Alzheimer's Disease. 1996 , 103-125			
40	Tau Phosphorylation and Dephosphorylation in the Pathogenesis of Alzheimer's Disease. 1996 , 109-126			
39	Potential Role of Hyperactivation of Signal Transduction Pathways in Alzheimer's Disease: Protein Kinase C Regulates PHF-like Phosphorylation of Tau within Neuronal Cells. 1996 , 447-467			
38	Pathological Changes in the Elderly Human Brain. 1997 , 5-114			
37	The Effect of Continuous Aerobic Exercise on Neurodegeneration in Diabetic Rats. <i>Annals of Military and Health Sciences Research</i> , 2018 , In Press,		1.3	
36	GSK-3 Inhibitors and Tooth Repair: An Ethical Analysis. <i>Frontiers in Pharmacology</i> , 2018 , 9, 1495		5.6	1
35	Autophagic Dysfunction in Neurodegeneration. <i>Advances in Medical Diagnosis, Treatment, and Care</i> , 2020 , 25-62		0.2	
34	Alzheimer Disease. 2005 , 79-93			
33	Judging a Protein by More Than Its Name: GSK-3. <i>Science Signaling</i> , 2001 , 2001, re12-re12		8.8	10
32	Somatodendritic localization and hyperphosphorylation of tau protein in transgenic mice expressing the longest human brain tau isoform. <i>EMBO Journal</i> , 1995 , 14, 1304-13		13	122
31	Cortical and brainstem-type Lewy bodies are immunoreactive for the cyclin-dependent kinase 5. <i>American Journal of Pathology</i> , 1995 , 147, 1465-76		5.8	85
30	Detection of a Cdc2-related kinase associated with Alzheimer paired helical filaments. <i>American Journal of Pathology</i> , 1995 , 146, 228-38		5.8	52
29	Extracellular signal regulated kinases. Localization of protein and mRNA in the human hippocampal formation in Alzheimer's disease. <i>American Journal of Pathology</i> , 1994 , 144, 565-72		5.8	69
28	Paired helical filament tau in Alzheimer's disease. The kinase connection. <i>American Journal of Pathology</i> , 1994 , 144, 449-53		5.8	72

27	Mechanical Stretching-Induced Traumatic Brain Injury Is Mediated by the Formation of GSK-3 β Tau Complex to Impair Insulin Signaling Transduction. <i>Biomedicines</i> , 2021 , 9,	4.8	
26	Intermittent hypoxia treatment alleviates memory impairment in the 6-month-old APP ^{swe} /PS1 ^{dE9} mice and reduces amyloid beta accumulation and inflammation in the brain. <i>Alzheimers Research and Therapy</i> , 2021 , 13, 194	9	0
25	N-terminal phosphorylation regulates the activity of Glycogen Synthase Kinase 3 from Plasmodium falciparum.. <i>Biochemical Journal</i> , 2022 ,	3.8	0
24	Role of proline-rich tyrosine kinase 2 (Pyk2) in the pathogenesis of Alzheimer's Disease.. <i>European Journal of Neuroscience</i> , 2021 ,	3.5	0
23	Diabetes: Risk Factor and Translational Therapeutic Implications for Alzheimer's Disease.. <i>European Journal of Neuroscience</i> , 2022 ,	3.5	0
22	The neuroprotective effects of icariin on ageing, various neurological, neuropsychiatric disorders, and brain injury induced by radiation exposure.. <i>Aging</i> , 2022 , 14,	5.6	1
21	Hyperphosphorylated Tau Relates to Improved Cognitive Performance and Reduced Hippocampal Excitability in the Young rTg4510 Mouse Model of Tauopathy.. <i>Journal of Alzheimers Disease</i> , 2022 ,	4.3	1
20	Molecular mechanisms of developmental pathways in neurological disorders: a pharmacological and therapeutic review.. <i>Open Biology</i> , 2022 , 12, 210289	7	1
19	Neuroprotective Effects of Green Tea Seed Isolated Saponin Due to the Amelioration of Tauopathy and Alleviation of Neuroinflammation: A Therapeutic Approach to Alzheimer's Disease.. <i>Molecules</i> , 2022 , 27,	4.8	0
18	GSK-3 β and its Inhibitors in Alzheimer's Disease: A Recent Update.. <i>Mini-Reviews in Medicinal Chemistry</i> , 2022 ,	3.2	0
17	Synthesis of functionalized flavones from 3-halo-2-(methylthio)-4H-chromen-4-ones. <i>Tetrahedron Letters</i> , 2022 , 153882	2	
16	Therapeutic targeting of glycogen synthase kinase-3: Strategy to address neurodegenerative diseases. 2022 , 535-569		
15	Altered amyloid precursor protein, tau-regulatory proteins, neuronal numbers and behaviour, but no tau pathology, synaptic and inflammatory changes or memory deficits, at 1 month following repetitive mild traumatic brain injury. <i>European Journal of Neuroscience</i> ,	3.5	0
14	d-Pinitol promotes tau dephosphorylation through a cyclin-dependent kinase 5 regulation mechanism: A new potential approach for tauopathies?. <i>British Journal of Pharmacology</i> ,	8.6	0
13	DYRK1a Inhibitor Mediated Rescue of Drosophila Models of Alzheimer's Disease-Down Syndrome Phenotypes. <i>Frontiers in Pharmacology</i> , 13,	5.6	1
12	Identification of CNS compatible small molecules as glycogen synthase kinase-3 β (GSK-3 β) inhibitors through structure-based virtual screening. 2022 , 31, 1545-1557		
11	Antimicrobial, Polarizing Light, and Paired Helical Filament Properties of Fragmented Tau Peptides of Selected Putative Gingipains. 2022 , 1-13		0
10	Combined targeting of pathways regulating synaptic formation and autophagy attenuates Alzheimer's disease pathology in mice. 13,		

- 9 Clinical Biomarkers and Novel Drug Targets to Cut Gordian Knots of Alzheimer's Disease. **2022**, 15, 0
- 8 Therapeutic Implications of Glycogen Synthase Kinase-3 β in Alzheimer's disease: A Novel Therapeutic Target. 1-27 1
- 7 The ubiquitous microtubule-associated protein 4 (MAP4) controls organelle distribution by regulating the activity of the kinesin motor. **2022**, 119, 0
- 6 Tau Protein as Therapeutic Target for Cancer? Focus on Glioblastoma. **2022**, 14, 5386 0
- 5 Study on multi-target effects of PIMPC on A β /Cu²⁺-induced Alzheimer's disease model of rats. **2023**, 1802, 148226 0
- 4 The impact of loneliness and social isolation on the development of cognitive decline and Alzheimer's Disease. **2023**, 101061 0
- 3 Aberrant accumulation of age- and disease-associated factors following neural probe implantation in a mouse model of Alzheimer's disease. 0
- 2 The Involvement of Post-Translational Modifications in Regulating the Development and Progression of Alzheimer's Disease. 0
- 1 Different Effects and Mechanisms of Selenium Compounds in Improving Pathology in Alzheimer's Disease. **2023**, 12, 702 0